Navigation Links
Genomic Profiling of Breast Cancers a Better Treatment Tool
Date:4/1/2008

Findings point to personalized therapies that help predict disease recurrence

TUESDAY, April 1 (HealthDay News) -- Determining the genetic profile of a breast tumor, along with an assessment of a patient's clinical characteristics, can help predict prognosis and guide treatment choices, a Duke University study concludes.

"Our goal is to treat patients on a more individualized basis, matching the right drugs with the right patients," Dr. Anil Potti, an oncologist and researcher in the Duke Comprehensive Cancer Center and Duke's Institute for Genome Sciences & Policy, said in a prepared statement.

"The combination of these two methods, one of which uses the clinical description of a patient's breast cancer and the other which looks at the gene expression at a molecular level in a patient's tumor, may allow us to do that with unprecedented accuracy. This represents a robust approach to personalizing treatment strategies in patients suffering from breast cancer," Potti said.

The team examined almost 1,000 breast tumors and corresponding patient data and used a computerized system called Adjuvant! to assess clinical characteristics and make predictions of recurrence. The researchers then compared gene expression in the tumor samples and were able to identify specific genomic patterns among patients with aggressive cancers and those with cancers less likely to recur.

"We knew from previous studies that Adjuvant! tends to overestimate disease recurrence in younger patients. We hypothesized that genomic profiling could be a complementary tool that would more precisely define clinical outcomes and could also help to aid in selecting the right drug for a given patient," Potti said.

Not only did their method identify patients at high risk for cancer recurrence, it specified the degree of that risk. For example, they could predict that a patient had a 90 percent risk of recurrence.

"This is important, because with this data, we might decide to treat this person more aggressively even than someone else who is considered 'high risk' but may have only a 60 percent likelihood of recurrence," Potti said. "Moreover, we can identify specific options for chemotherapy in such patients as well, by correlating gene expression in a tumor with its response, or non-response, to certain chemotherapies."

The study was published in the April 2 issue of the Journal of the American Medical Association.

This study "demonstrates the potential value of using microarray-based gene signatures to refine outcome predictions," Chiang-Ching Huang and Markus Bredel, of the Feinberg School of Medicine at Northwestern University in Chicago, wrote in an accompanying editorial.

"In an attempt to tailor risk estimation, these investigators shy away from pure metagene predictors but instead focus on genes with mechanistic implication in breast cancer. Because these genes represent potential targets for specific molecular therapy, this approach represents an advance in the changing landscape of oncology toward individualized patient management," they wrote.

More information

The American Cancer Society has more about breast cancer.



-- Robert Preidt



SOURCES: Duke University, news release; JAMA/Archives journals, news release, both April 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genomic Profiling of Breast Cancers a Better Treatment Tool
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, ... a medical article to the newly revamped Cosmetic Town journal section, ... hair transplant procedure known as Follicular Unit Extraction (FUE). , Dr. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
Breaking Medicine Technology: